Alterity Therapeutics Limited, a pharmaceutical company specializing in the development of therapeutic drugs, has announced its compliance with the Takeovers Panel General Guidance Note 20. The ...

CD&R has named Sam Camens as managing director. In this role, Camens will drive CD&R’s health and welfare strategy. Previously, he was managing director of insurance and benefits at Onex. He is the ...

Alterity Therapeutics Ltd. ( ($AU:ATH) ) has shared an announcement. Alterity Therapeutics Limited has announced the issuance ...

Benchmark analyst Robert Wasserman downgraded Alterity Therapeutics (ATHE) to Hold from Speculative Buy.Maximize Your Portfolio with Data ...

Alterity Therapeutics Ltd. reported positive top-line phase II results for lead candidate ATH-434 for treating multiple system atrophy, a rare neurological disorder similar to Parkinson's disease.

This week’s Bulls N’ Bears Runner of the Week is… Bio-Gene Technology. The company’s shares leapt after revealing it scored a slice of two US defence grants.

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a ...

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) were trading at $55, up $29.28, or 113%, on positive interim data from the phase Ib acute hemodynamic trial of its lead product candidate, TX-45.

This week’s Bulls N’ Bears Runner of the Week is… Bio-Gene Technology. The company’s shares leapt after revealing it scored a ...

Alterity Therapeutics (NASDAQ: ATHE) shares moved up at warp-speed Thursday, on announcing positive topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical ...

Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.